Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs

Marisa K. Ames Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Marisa K. Ames in
Current site
Google Scholar
PubMed
Close
 DVM
,
Clarke E. Atkins Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Clarke E. Atkins in
Current site
Google Scholar
PubMed
Close
 DVM
,
Seunggon Lee Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Seunggon Lee in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Andrea C. Lantis Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Andrea C. Lantis in
Current site
Google Scholar
PubMed
Close
 DVM
, and
James R. zumBrunnen Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by James R. zumBrunnen in
Current site
Google Scholar
PubMed
Close
 MS

Abstract

OBJECTIVE To determine whether high doses of enalapril and benazepril would be more effective than standard doses of these drugs in suppressing the furosemide-activated renin-angiotensin-aldosterone system (RAAS).

ANIMALS 6 healthy Beagles.

PROCEDURES 2 experiments were conducted; each lasted 10 days, separated by a 2-week washout period. In experiment 1, all dogs received furosemide (2 mg/kg, PO, q 12 h) and enalapril (1 mg/kg, PO, q 12 h) for 8 days (days 0 through 7). In experiment 2, dogs received furosemide (2 mg/kg, PO, q 12 h) and benazepril (1 mg/kg, PO, q 12 h) for 8 days. Effects on the RAAS were determined by assessing serum angiotensin-converting enzyme (ACE) activity on days −1, 3, and 7; serum aldosterone concentration on days −2, −1, 1, 3, and 7; and the urinary aldosterone-creatinine ratio (UAldo:C) in urine collected in the morning and evening of days −2, −1, 1, 3, and 7.

RESULTS High doses of enalapril and benazepril caused significant reductions in serum ACE activity on all days but were not more effective than standard doses used in other studies. Mean UAldo:C remained significantly higher on days 2 through 7, compared with baseline values. Serum aldosterone concentration also increased after drug administration, which mirrored changes in the UAldo:C.

CONCLUSIONS AND CLINICAL RELEVANCE In this study, administration of high doses of enalapril and benazepril significantly inhibited ACE activity, yet did not prevent increases in mean urine and serum aldosterone concentrations resulting from furosemide activation of RAAS. This suggested that aldosterone breakthrough from ACE inhibition was a dose-independent effect of ACE inhibitors.

Abstract

OBJECTIVE To determine whether high doses of enalapril and benazepril would be more effective than standard doses of these drugs in suppressing the furosemide-activated renin-angiotensin-aldosterone system (RAAS).

ANIMALS 6 healthy Beagles.

PROCEDURES 2 experiments were conducted; each lasted 10 days, separated by a 2-week washout period. In experiment 1, all dogs received furosemide (2 mg/kg, PO, q 12 h) and enalapril (1 mg/kg, PO, q 12 h) for 8 days (days 0 through 7). In experiment 2, dogs received furosemide (2 mg/kg, PO, q 12 h) and benazepril (1 mg/kg, PO, q 12 h) for 8 days. Effects on the RAAS were determined by assessing serum angiotensin-converting enzyme (ACE) activity on days −1, 3, and 7; serum aldosterone concentration on days −2, −1, 1, 3, and 7; and the urinary aldosterone-creatinine ratio (UAldo:C) in urine collected in the morning and evening of days −2, −1, 1, 3, and 7.

RESULTS High doses of enalapril and benazepril caused significant reductions in serum ACE activity on all days but were not more effective than standard doses used in other studies. Mean UAldo:C remained significantly higher on days 2 through 7, compared with baseline values. Serum aldosterone concentration also increased after drug administration, which mirrored changes in the UAldo:C.

CONCLUSIONS AND CLINICAL RELEVANCE In this study, administration of high doses of enalapril and benazepril significantly inhibited ACE activity, yet did not prevent increases in mean urine and serum aldosterone concentrations resulting from furosemide activation of RAAS. This suggested that aldosterone breakthrough from ACE inhibition was a dose-independent effect of ACE inhibitors.

Contributor Notes

Dr. Ames’ present address is the Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Dr. Lee's present address is Choonghyun Animal Hospital, 191-2 Nonhyeon-ro, Gangnam-gu, Seoul, 135-080, Republic of Korea.

Dr. Lantis’ present address is Veterinary Emergency and Referral Group, 318 Warren St, Brooklyn, NY 11201.

Mr. zumBrunnen's present address is Department of Statistics, College of Natural Sciences, Colorado State University, Fort Collins, CO 80523.

Address correspondence to Dr. Ames (marisa.ames@colostate.edu).
  • 1. Levine TB, Francis GB, Goldsmith SR, et al., Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 16591666.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Broqvist M, Dahlstrom U, Karlberg BE, et al., Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J 1989; 10: 10751083.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 17241729.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Girerd N, Pang PS, Swedberg K, et al., Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail 2013; 15: 12281235.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Weber KT, Brilla CG. Pathological hypertrophy and cardiac in-terstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 18491869.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992; 19: 270277.

  • 7. Brilla CG, Rupp H, Funck R, et al., The renin-angiotensin-aldosterone system and myocardial collagen matrix remodeling in congestive heart failure. Eur Heart J 1995; 16 (suppl O): 107109.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Zannad F. Aldosterone and heart failure. Eur Heart J 1995; 16 (suppl N): 98102.

  • 9. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 16891697.

  • 10. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577585.

  • 11. Martinez FA. Aldosterone inhibition and cardiovascular protection: more important than it once appeared. Cardiovasc Drugs Ther 2010; 24: 345350.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Dube P, Weber KT. Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part II. Am J Med Sci 2011; 342: 503506.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Dzau VJ, Colucci WS, Hollenberg NK, et al., Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645651.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Lovern CS, Swecker WS, Lee JC, et al., Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs. Am J Vet Res 2001; 62: 17931796.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Atkins CE, Rausch WP, Gardner SY, et al., The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog. J Vet Pharmacol Ther 2007; 30: 394400.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med 1995; 9: 243252.

    • Search Google Scholar
    • Export Citation
  • 17. Ettinger SJ, Benitz AM, Ericsson GF, et al., Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998; 213: 15731577.

    • Search Google Scholar
    • Export Citation
  • 18. The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomised, double-blinded, placebo-controlled, long term clinical trial. J Vet Cardiol 1999; 1: 718.

    • Search Google Scholar
    • Export Citation
  • 19. Amberger C, Chetboul V, Bomassi E, et al., Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol 2004; 6: 916.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Atkins C, Bonagura J, Ettinger S, et al., Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 11421150.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21. Pitt B, Zannad F, Remme WJ, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709717.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Pitt B, Remme W, Zannad F, et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 13091321.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. Zannad F, McMurray JJ, Krum H, et al., Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 1121.

  • 24. Bernay F, Bland JM, Häggström J, et al., Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24: 331341.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Lantis AC, Atkins CE, DeFrancesco TC, et al., Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs. Am J Vet Res 2011; 72: 16461651.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26. Lantis AC, Ames MK, Atkins CE, et al., Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs. J Vet Pharmacol Ther 2015; 38: 6573.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27. Gardner SY, Atkins CE, Rausch WP, et al., Estimation of 24-h aldosterone secretion in the dog using the urine aldosterone:creatinine ratio. J Vet Cardiol 2007; 9: 17.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28. MacFadyen RJ, Lee AFC, Morton JJ, et al., How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 5761.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29. Lee AFC, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1: 401406.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30. Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000; 2: 451456.

  • 31. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486492.

  • 32. Bomback AS, Rekhtman Y, Klemmer PJ, et al., Aldosterone breakthrough during aliskiren, valsartan, and combination (alisiren + valsartan) therapy. J Am Soc Hypertens 2012; 6: 338345.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33. Ames MK, Atkins CE, Lantis AC, et al., Effect of high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs. Am J Vet Res 2013; 74: 10841090.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34. Sayer MB, Atkins CE, Fujii Y, et al., Acute effects of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs. J Vet Intern Med 2009; 23: 10031006.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35. Toutain PL, Lefebvre HP, King JN. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamics modeling approach. J Pharmacol Exp Ther 2000; 292: 10871093.

    • Search Google Scholar
    • Export Citation
  • 36. Toutain PL, Lefebvre HP. Pharmacokinetics and pharmacokinetic/pharmacodynamics relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther 2004; 27: 515525.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37. Dzau VJ, Bernstein K, Celermajer D, et al., The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (suppl): 1L20L.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008; 86: 615621.

  • 39. Bader M., Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol 2010;50: 439465.

  • 40. Cheng Meng Q, Balcells E, Dell'Italia L, et al., Sensitive method for quantification of angiotensin-converting enzyme (ACE) activity in tissue. Biochem Pharmacol 1995; 50: 14451450.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41. Koiter J, Navis G, de Jong PE, et al., Sample dilution: a methodological pitfall in the measurement of tissue but not serum ACE-activity. J Pharmacol Toxicol 1998; 39: 4549.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42. Sauer WH, Baer JT, Berlin JA, et al., Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction. Am J Cardiol 2004; 94: 11711173.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43. Tu K, Mamdani M, Kopp A, et al., Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 2005; 95: 283286.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44. Ruzicka M, Skarda V, Frans LHH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995; 92: 35683573.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45. Tang WHW, Vagelos RH, Yin-Gail Y, et al., Neurohormonal and clinical response to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 7078.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46. Davidson NC, Coutie WJ, Webb DJ, et al., Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 1996; 75: 576581.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47. Schjoedt KJ, Andersen S, Rossing P, et al., Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 19361939.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48. Briones AM, Ngyuen DC, Callera GE, et al., Adipocytes produce aldosterone through calcineurin-dependent signaling pathways. Hypertension 2012; 59: 10691078.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49. Meurs KM, Chdid L, Reina-Doreste Y, et al., Polymorphisms in the canine and feline renin-angiotensin-aldosterone system genes. Anim Genet 2015; 46: 226.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50. Zadik Z, Levin P, Kowarski A. The diagnostic value of the 24 hour integrated concentration of plasma aldosterone. Clin Exp Hypertens A 1985; 7: 12331242.

    • Search Google Scholar
    • Export Citation
  • 51. Carmichael DJ, Sutters MS, Unwin RJ, et al., Time-course and relationship of the early changes in renal sodium excretion and aldosterone secretion during dietary sodium restriction in normal man. Clin Sci (Lond) 1990; 78: 605612.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52. Tolagen K, Karlberg BE. Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects. Scand J Clin Lab Invest 1978; 38: 241247.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53. Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67: 403413.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54. Steegers EA, Benraad TJ, Jongsma HW, et al., Effects of dietary sodium restriction and posture on plasma levels of atrial natriuretic peptide, aldosterone and free aldosterone in normal human pregnancy. J Endocrinol 1990; 124: 507513.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55. Mann DL, Management of heart failure patients with reduced ejection fraction. In: Libby P, Bonow RO, Mann DL, et al, eds. Braunwald's heart disease. 8th ed. Philadelphia: Saunders Elsevier, 2008;611640.

    • Search Google Scholar
    • Export Citation
  • 56. Adin DB, Taylor AW, Hill RC, et al., Intermittent bolus injection versus continuous infusion of furosemide in normal adult Greyhound dogs. J Vet Intern Med 2003; 17: 632636.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement